Five dividend stocks are drawing attention from income investors looking for reliable payouts and solid long-term value. Each company brings something different to the table, from monthly income to pharmaceutical growth.
Realty Income is known simply as “The Monthly Dividend Company.” It owns thousands of commercial properties leased to major tenants under long-term contracts.
The stock yields above 5% and has raised its dividend more than 120 times since going public. Its portfolio spans retail, industrial, gaming, and other property types, which helps spread risk.
Analyst ratings sit at 7 Buy, 7 Hold, and 1 Sell, with an average price target of around $67.35.
Verizon has raised its dividend every year for close to two decades. The company generates steady cash flow from its wireless and broadband businesses.
Verizon Communications Inc., VZ
Growth has been slow, but Verizon’s services are essential, and its customer base is large. Investors tend to choose it for income and lower volatility rather than price appreciation.
It remains one of the highest-yielding large-cap stocks in the U.S. market.
Pfizer has seen earnings slow since the peak of its COVID vaccine revenue. The stock’s yield has risen as the share price has pulled back, attracting income-focused investors.
The company still has a broad pipeline and continues spending on research and development. Newer drugs in its portfolio could help fill the revenue gap left by declining pandemic-related sales.
Investors who can wait may benefit if Pfizer’s newer products gain traction over the next few years.
Chevron is one of the most respected dividend payers in the energy sector. The company has kept shareholder returns intact across multiple oil price cycles, which sets it apart from many peers.
Its balance sheet is strong and it returns cash through both dividends and share buybacks. While the stock can move with oil prices, its financial discipline has made it a long-term favorite.
For investors who want energy exposure alongside reliable income, Chevron is a top pick in the sector.
AbbVie has made a clean transition away from its reliance on Humira. Newer drugs Skyrizi and Rinvoq are growing fast and have helped the company beat analyst expectations in recent quarters.
Management has raised guidance as those products continue gaining ground. The dividend track record is strong, and analysts are broadly positive on the outlook.
AbbVie carries a Moderate Buy consensus rating from 19 analysts, with no Sell ratings and an average price target of around $253.43.
The post Best High-Yield Dividend Stocks to Watch in 2026: Verizon, Chevron, Pfizer Top the List appeared first on CoinCentral.
